Expression of phosphorylated Akt in patients with small cell carcinoma of the lung indicates good prognosis

Pathology International

Volumn 60, Issue 11, 2010, Pages 714-719

  Ikeda, Satoshi ^a   Takabe, Kazuhiko ^a   Inagaki, Masaharu ^a   Suzuki, Keiko ^a  

^a TSUCHIURA KYODO GENERAL HOSPITAL   (Japan)

Author keywords

Phosphorylated Akt; Phosphorylated mTOR; Prognosis; Small cell lung cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUCURONOSYLTRANSFERASE; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; URIDINE DIPHOSPHATE GLUCURONOSYL TRANSFERASE 1A1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHORYLATION; POLYMORPHISM, GENETIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 77958496580     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2010.02594.x     Document Type: Article

References (13)

1. Han JY, Lim HS, Shin ES et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 2006; 24: 2237-44.
2. Ikeda S, Takabe K, Suzuki K. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathol Int 2009; 59: 863-7.
3. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
4. Ikeda S, Takabe K, Inagaki M et al. Correlation between EGFR gene mutation pattern and Akt phosphorylation in pulmonary adenocarcinomas. Pathol Int 2007; 57: 268-75.
5. Lim WT, Zhang WH, Miller CR et al. PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep 2007; 17: 853-7.
6. Skov BG, Holm B, Erreboe A, Skov T, Mellemgaard A. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: Distribution and impact on survival. J Thorac Oncol 2010; 5: 453-9.
7. Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006; 51: 181-91.
8. Lim J, Kim JH, Paeng JY et al. Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol 2005; 58: 1199-205.
9. Dai DL, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases. J Clin Oncol 2005; 23: 1473-82.
10. Chadha KS, Khoury T, Yu J et al. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol 2006; 13: 933-9.
11. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-55.
12. Javle MM, Yu J, Khoury T et al. Akt expression may predict favorable prognosis in cholangiocarcinoma. J Gastroenterol Hepatol 2006; 21: 1744-51.
13. Shah A, Swain WA, Richardson D et al. Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11: 2930-36.